Journal article

Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; A Pneumocarr meeting report March 27-28, 2012, Geneva

D Goldblatt, M Ramakrishnan, K O'Brien

Vaccine | ELSEVIER SCI LTD | Published : 2013

Abstract

An international consultation was convened in March 2012 to provide feedback on the Case for Carriage, a summary statement by the Pneumococcal Carriage Consortium (PneumoCarr) proposing nasopharyngeal (NP) colonization as a supplementary or alternative endpoint in vaccine licensure. PneumoCarr members provided information to vaccine manufacturers, regulators and the WHO on the evidence for NP carriage as a precursor to pneumococcal disease, standardization of laboratory methods for the detection of multiple serotype carriage, definition and estimation of pneumococcal vaccine efficacy against carriage (VE-col), and the direct and indirect impact of vaccination on carriage. Manufacturers and r..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

KOB: research grant support from Pfizer, and GlaxoSmithKline and has served on pneumococcal external expert committees convened by Merck, Aventis-pasteur, and GlaxoSmithKline.RD: grants/research support from Berna/Crucell, Wyeth/Pfizer, MSD, Protea; has been a scientific consultant for Berna/Crucell, GlaxoSmithKline, Novartis, Wyeth/Pfizer, Protea, MSD and a speaker for Berna/Crucell, GlaxoSmithKline, Wyeth/Pfizer; he is a shareholder of Protea/NASVAX.AS: has received research grant support from GSK and travel and accommodation support to attend a meeting convened by Merck.